Entera Bio Ltd. Non Cash Items (Other)

Non Cash Items (Other) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non Cash Items (Other) growth rates and interactive chart.


Highlights and Quick Summary

  • Non Cash Items (Other) for the quarter ending June 29, 2020 was $57 Thousand (a -86.62% decrease compared to previous quarter)
  • Year-over-year quarterly Non Cash Items (Other) decreased by -88.51%
  • Annual Non Cash Items (Other) for 2019 was $919 Thousand (a -7.73% decrease from previous year)
  • Annual Non Cash Items (Other) for 2018 was $996 Thousand (a -82.8% decrease from previous year)
  • Twelve month Non Cash Items (Other) ending June 29, 2020 was $1.45 Million (a 58.08% increase compared to previous quarter)
  • Twelve month trailing Non Cash Items (Other) increased by 55.87% year-over-year
Trailing Non Cash Items (Other) for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$1.45 Million $916 Thousand $919 Thousand $929 Thousand
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non Cash Items (Other) of Entera Bio Ltd.

Most recent Non Cash Items (Other)of ENTX including historical data for past 10 years.

Interactive Chart of Non Cash Items (Other) of Entera Bio Ltd.

Entera Bio Ltd. Non Cash Items (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.06 $0.43
2019 $0.47 $0.5 $-0.48 $0.43 $0.92
2018 $0.48 $2.79 $-3.5 $1.23 $1.0
2017 $5.79

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.